| 证券代码:300406 | | --- | | 债券代码:123150 | 证券代码：300406 证券简称：九强生物 公告编号：2026-008 债券代码：123150 债券简称：九强转债 一、专利基本情况 | 序号 | 专利号 | 专利名称 | 专利权人 | 专利类型 | 申请日期 | 授权日期 | | 证书号 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | ZL202310 811498.9 | 偶联物的制 备方法 | 九强生物 | 发明 | 2019.12.27 | 2026.02.10 | 第 | 8702944 | 号 | 注：发明专利权期限为自申请日起二十年。 发明专利摘要： 本专利涉及偶联物的制备方法。具体而言，本专利的 6-磷酸葡萄糖脱氢酶 突变体相较于野生型 6-磷酸葡萄糖脱氢酶包含选自以下的一个突变或其组合： D306C、D375C、G426C。使用本专利的 6-磷酸葡萄糖脱氢酶突变体所制备的检测 试剂盒，其特异性强、灵敏度高、操作方便、检测时间短、定量准确，适合高通 量检测。 二、对公司 ...

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

Core Viewpoint - Jiukang Bio has received a medical device registration certificate from the Beijing Drug Administration for its fibrin (original) degradation product determination kit (latex immunoturbidimetry method) [2] Group 1 - The product is named fibrin (original) degradation product determination kit [2] - The approval was granted by the Beijing Drug Administration [2] - The announcement was made on February 9 [2]

九强生物公告称，近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品为纤维蛋白（原） 降解产物测定试剂盒（胶乳免疫比浊法），注册证编号为京械注准20262400041，注册类别为Ⅱ，有效 期至2031年2月4日，用于体外定量检测人血浆中纤维蛋白（原）降解产物含量。 ...

上述产品医疗器械注册证的取得，丰富了公司在体外诊断血凝细分领域 产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公 司未来的经营将产生积极影响。上述产品实际销售情况取决于未来市场推广 效果，公司目前尚无法预测其对公司未来业绩的影响，敬请投资者注意投资 风险。 特此公告。 北京九强生物技术股份有限公司 董事会 关于公司取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 纤维蛋白（原）降解 产物测定试剂盒（胶 乳免疫比浊法） | 京 械 注 准 20262400041 | Ⅱ | 自批准之日起有效期 至 2031 年 02 月 04 日 | 本试剂盒用于体外定量 检测人血浆中的纤维蛋 白（原）降解产物（FDP） 含量。 | | ...

内容概要：随着生物技术的飞速发展，数字PCR仪作为新一代的核酸检测技术，正逐渐在生命科学研 究、临床诊断、食品安全检测等领域崭露头角。数字PCR仪的出现，为核酸定量分析提供了更精确、更 灵敏的方法，弥补了传统PCR技术的一些局限性，被广泛认为是PCR技术发展的重要里程碑。在过去的 几年中，中国数字PCR仪市场规模呈现出稳健的增长态势。数据显示，2019-2025年中国数字PCR仪行 业市场规模从15.84亿元增长至88.15亿元，年复合增长率为33.1%。这一增长不仅得益于技术优势的驱 动，还得益于国家政策的支持。预计未来随着数字PCR仪的不断推广和应用，科研人员、临床医生以及 相关行业从业者对其优势和应用价值的认识逐渐加深，市场接受度不断提高，将进一步推动了市场需求 的增长。 相关上市企业：迈克生物（300463）、普门科技（688389）、科华生物（002022）、安图生物 （603658）、万孚生物（300482）、亚辉龙（688575）、美康生物（300439）、九强生物（300406）、 中源协和（600645）等。 相关企业：北京新羿生物科技有限公司、臻准生物科技（上海）有限公司、领航基因科技（杭 ...

Core Viewpoint - The company, Jiukang Biotechnology, has evolved from a代理商 to a leading player in the IVD (in vitro diagnostics) industry in China, focusing on innovation and precision diagnosis to drive future growth [2][3]. Group 1: Company Development - Jiukang Biotechnology started as an代理商 for an international IVD brand and quickly gained recognition, becoming a service supplier for the national quality control products [3]. - The company has maintained a strong client base, with over 70% of top-tier hospitals in China being loyal customers [3]. - The company has significantly increased its R&D investment, with R&D accounting for 21% of sales revenue in the first three quarters of 2025, up from 14% in the same period of 2024 [3]. Group 2: Product Innovation - R&D efforts are focused on new products in areas such as pathology, chemiluminescence, and coagulation, leading to an increase in medical device registrations and patents [4]. - The company has launched new products, including a high-speed fully automated chemiluminescence immunoassay analyzer and a biochemical analyzer, enhancing its competitive edge in the market [4]. - Jiukang's first AI project, a prostate cancer AI interpretation software, has been developed and validated, with plans to expand into smart pathology products [4]. Group 3: Strategic Partnerships - The company aims to become a platform enterprise in the IVD sector, collaborating with leading international firms to leverage their strengths and expand into global markets [5]. - A strategic partnership with Abbott began in 2013, allowing Jiukang to share its patented processes for global product production, resulting in profit-sharing [6]. - In 2020, a significant partnership with China National Pharmaceutical Group (Sinopharm) was established, enhancing sales channels and accelerating growth, with Sinopharm becoming the largest shareholder [6]. Group 4: Industry Trends - The IVD industry in China is rapidly developing, with significant growth potential driven by medical reform and innovation [7]. - The industry is expected to undergo a transformation towards high-quality upgrades, with a focus on value competition rather than price competition [7]. - Emerging technologies such as molecular diagnostics and AI-assisted diagnostics are anticipated to become core competitive advantages, with an emphasis on domestic alternatives in high-end markets [7].

截至2026年1月28日收盘，九强生物(300406)报收于13.89元，下跌2.87%，换手率2.43%，成交量10.31万 手，成交额1.44亿元。 当日关注点 交易信息汇总 资金流向 九强生物发布业绩预告，预计2025年全年扣非后净利润盈利1.71亿元至2.11亿元。九强生物发布业绩预 告，预计2025年全年归属净利润盈利1.8亿元至2.18亿元。 公司公告汇总 2025年度业绩预告 北京九强生物技术股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为18,000万 元至21,800万元，较上年同期下降66.21%至59.07%。扣除非经常性损益后的净利润预计为17,093万元至 21,093万元，同比下降67.16%至59.48%。业绩下降主要由于控股子公司美创公司受医疗行业政策影响， 拟计提商誉减值准备约1.8亿元，以及主营业务受政策影响导致盈利能力下滑。非经常性损益对净利润 的影响为707万元，主要为政府补助。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自【交易信息汇总】：1月28日主力资金净流 ...

格隆汇1月28日丨九强生物(300406.SZ)公布，预计2025年归属于上市公司股东的净利润18,000万元～ 21,800万元，比上年同期下降66.21%～59.07%，扣除非经常性损益后的净利润17,093万元～21,093万 元，比上年同期下降67.16%～59.48%。 公司控股子公司美创公司受医疗行业政策影响，量价承压，行业竞争日益加剧，经营受到很大影响，出 于谨慎性原则，判断相关资产组商誉存在减值迹象，公司本期拟计提商誉减值准备约1.8亿元。截至本 公告披露日，相关商誉减值测试工作尚在进行中，最终商誉减值准备计提金额，将在公司聘请的具备证 券期货从业资格的评估机构及审计机构进行评估和审计的基础上，由公司履行内部的相关程序后确定。 ...

证券日报网讯 1月28日，九强生物发布公告称，公司预计2025年度归属于上市公司股东的净利润为18， 000万元-21，800万元，比上年同期53，263.53万元下降66.21%-59.07%。 （编辑 袁冠琳） ...